RecruitingPhase 3NCT07115004

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients With Von Willebrand Disease (VIVID-6)

Sponsor

Vega Therapeutics, Inc

Enrollment

60 participants

Start Date

Oct 15, 2025

Study Type

INTERVENTIONAL

Conditions

Von Willebrand Disease (vWD)

Summary

This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)

Eligibility

Min Age: 12 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VGA039 for people with von willebrand disease (vwd). The study is currently recruiting participants at 14 locations. People eligible for this study include aged 12 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVGA039

VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.

Locations(32)

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Luskin Orthopaedic Institute For Children

Los Angeles, California, United States

Stanford University

Palo Alto, California, United States

UC Davis Medical Center

Sacramento, California, United States

University of California San Francisco

San Francisco, California, United States

Yale University School of Medicine

New Haven, Connecticut, United States

Emory University Hospital

Atlanta, Georgia, United States

Children's Healthcare of Atlanta

Atlanta, Georgia, United States

University of Michigan Health

Ann Arbor, Michigan, United States

University of Minnesota

Minneapolis, Minnesota, United States

Science 37, Inc. (Virtual Clinical MetaSite)

Morrisville, North Carolina, United States

Hemophilia Center of Western PA

Pittsburgh, Pennsylvania, United States

UT Southwestern Children's Hospital

Dallas, Texas, United States

Washington Center for Bleeding Disorders

Seattle, Washington, United States

Royal Prince Alfred Hospital, Institute of Haematology

Sydney, New South Wales (nsw), Australia

Royal Brisbane & Women's Hospital (RBWH), Queensland Haemophilia Centre

Brisbane, Queensland, Australia

The Alfred Hospital (Alfred Health),Monash University

Melbourne, Victoria, Australia

Medical University of Vienna

Vienna, Austria

Multihemo - Oncoclínicas

Recife, Pernambuco, Brazil

Centro de Hemoterapia e Hematologia do Rio de Janeiro (HEMORIO)

Rio de Janeiro, Rio de Janeiro, Brazil

emocentro UNICAMP (Centro de Hematologia e Hemoterapia da UNICAMP), University of Campinas (UNICAMP)

Campinas, São Paulo, Brazil

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)

São Paulo, São Paulo, Brazil

K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი)

Tbilisi, Georgia

Vivantes Klinikum im Friedrichshain

Berlin, Germany

Frankfurt University Hospital (Universitätsmedizin Frankfurt)

Frankfurt, Germany

St. James's Hospital, National Coagulation Centre

Dublin, Dublin, Ireland

University of Milan

Milan, Milan, Italy

Azienda Ospedaliero-Universitaria Careggi (Careggi University Hospital)

Florence, Italy

Worthwhile Clinical Trials Lakeview Hospital

Benoni, Gauteng, South Africa

Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist

Johannesburg, South Africa

Imperial College Healthcare NHS Trust, Hammersmith Hospital

London, Greater London, United Kingdom

Royal Free London NHS Foundation Trust,

London, London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07115004

Related Trials

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

NCT07575308

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

NCT0558299321 locations

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT0675485225 locations

A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease

NCT076408939 locations

Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease

NCT0665125517 locations